HDAC-inhibitor (S)-8 disrupts HDAC6-PP1 complex prompting A375 melanoma cell growth arrest and apoptosis

Journal of Cellular and Molecular Medicine

Volumn 19, Issue 1, 2015, Pages 143-154

  Balliu, Manjola ^a   Guandalini, Luca ^b   Romanelli, Maria Novella ^b   D'Amico, Massimo ^a   Paoletti, Francesco ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

AKT; A375 human melanoma cells; Apoptosis; Differentiation; Growth arrest; HDAC inhibitor (S) 8; HDAC6; HDAC6 PP1 complex; in vivo toxicity; Protein phosphatase 1 (PP1)

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CASPASE; DIBENZAZEPINE DERIVATIVE; HDAC6 PROTEIN, HUMAN; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; N1-HYDROXY-N8-(1-METHYL-2-OXO-5-PHENYL-2,3-DIHYDRO-1H-BENZO(E)(1,4)DIAZEPIN-3-YL)OCTANEDIAMIDE; PHOSPHOPROTEIN PHOSPHATASE 1;

ANGIOGENESIS; ANIMAL; APOPTOSIS; CELL MOTION; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; FEMALE; HUMAN; MALE; MELANOCYTE; MELANOMA; METABOLISM; MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; STEREOISOMERISM; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BENZODIAZEPINONES; CASPASES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DIBENZAZEPINES; FEMALE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MALE; MELANOCYTES; MELANOMA; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN PHOSPHATASE 1; SIGNAL TRANSDUCTION; STEREOISOMERISM;

EID: 84921496030     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12345     Document Type: Article

References (42)

1. Marks P, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001; 3: 194-202.
2. Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev. 1999; 9: 40-8.
3. Monneret C. Histone deacetylase inhibitors. Eur J Med Chem. 2005; 40: 1-13.
4. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006; 5: 769-84.
5. Marks PA, Xu WS. Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem. 2009; 107: 600-8.
6. Mai A, Altucci L. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. Int J Biochem Cell Biol. 2009; 41: 199-213.
7. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov. 2002; 1: 287-99.
8. Glozak MA, Sengupta N, Zhang X, et al. Acetylation and deacetylation of non-histone proteins. Gene. 2005; 363: 15-23.
9. Dokmanovic M, Marks PA. Prospects: histone deacetylase inhibitors. J Cell Biochem. 2005; 96: 293-304.
10. Bots M, Johnstone RW. Rational combinations using HDAC inhibitors. Clin Cancer Res. 2009; 15: 3970-7.
11. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol. 2007; 25: 84-90.
12. Marquard L, Poulsen CB, Gjerdrum LM, et al. Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas. Histopathology. 2009; 54: 688-98.
13. Guandalini L, Cellai C, Laurenzana A, et al. Design, synthesis and preliminary biological evaluation of new hydroxamate histone deacetylase inhibitors as potential antileukemic agents. Bioorg Med Chem Lett. 2008; 18: 5071-4.
14. Cellai C, Balliu M, Laurenzana A, et al. The new low-toxic histone deacetylase inhibitor S-(2) induces apoptosis in various acute myeloid leukemia cells. J Cell Mol Med. 2012; 16: 1758-65.
15. Laurenzana A, Balliu M, Cellai C, et al. Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells. PLoS ONE. 2013; 8: e58267.
16. Guandalini L, Balliu M, Cellai C, et al. Design, synthesis and preliminary evaluation of a series of histone deacetylase inhibitors carrying a benzodiazepine ring. Eur J Med Chem. 2013; 66: 56-68.
17. Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline-Update 2012. Eur J Cancer. 2012; 48: 2375-90.
18. Finn L, Markovic SN, Joseph RW. Therapy for metastatic melanoma: the past, present, and future. BMC Med. 2012; 10: 23-33.
19. Tanemura A, Kiyohara E, Katayama I, et al. Recent advances and developments in the antitumor effect of the HVJ envelope vector on malignant melanoma: from the bench to clinical application. Cancer Gene Ther. 2013; 20: 599-605.
20. Laurenzana A, Cellai C, Vannucchi AM, et al. WEB-2086 and WEB-2170 trigger apoptosis in both ATRA-sensitive and -resistant promyelocytic leukemia cells and greatly enhance ATRA differentiation potential. Leukemia. 2005; 19: 390-5.
21. Cellai C, Laurenzana A, Bianchi E, et al. Mechanistic insight into WEB-2170-induced apoptosis in human acute myelogenous leukemia cells: the crucial role of PTEN. Exp Hematol. 2009; 37: 1176-85 e21.
22. Salvioli S, Ardizzoni A, Franceschi C, et al. JC-1, but not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to assess delta psi changes in intact cells: implications for studies on mitochondrial functionality during apoptosis. FEBS Lett. 1997; 411: 77-82.
23. Gerdes J, Schwab U, Lemke H, et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983; 31: 13-20.
24. Nitoda T, Fan MD, Kubo I. Anisaldehyde, a melanogenesis potentiator. Z Naturforsch C. 2007; 62: 143-9.
25. Leber TM, Balkwill FR. Zymography: a single-step staining method for quantitation of proteolytic activity on substrate gels. Anal Biochem. 1997; 249: 24-8.
26. Shi Y. Serine/threonine phosphatases: mechanism through structure. Cell. 2009; 139: 468-84.
27. Lee YS, Lim KH, Guo X, et al. The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. Cancer Res. 2008; 68: 7561-9.
28. Luo J, Su F, Chen D, et al. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature. 2000; 408: 377-81.
29. Richon VM, Sandhoff TW, Rifkind RA, et al. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA. 2000; 97: 10014-9.
30. Hubbert C, Guardiola A, Shao R, et al. HDAC6 is a microtubule-associated deacetylase. Nature. 2002; 417: 455-8.
31. Liotta LA, Tryggvason K, Garbisa S, et al. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 1980; 284: 67-8.
32. Bernhard EJ, Gruber SB, Muschel RJ. Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc Natl Acad Sci USA. 1994; 91: 4293-7.
33. Tsunezuka Y, Kinoh H, Takino T, et al. Expression of membrane-type matrix metalloproteinase 1 (MT1-MMP) in tumor cells enhances pulmonary metastasis in an experimental metastasis assay. Cancer Res. 1996; 56: 5678-83.
34. Naito K, Kanbayashi N, Nakajima S, et al. Inhibition of growth of human tumor cells in nude mice by a metalloproteinase inhibitor. Int J Cancer. 1994; 58: 730-5.
35. Hua J, Muschel RJ. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res. 1996; 56: 5279-84.
36. Brush MH, Guardiola A, Connor JH, et al. Deacetylase inhibitors disrupt cellular complexes containing protein phosphatases and deacetylases. J Biol Chem. 2004; 279: 7685-91.
37. Favre B, Turowski P, Hemmings BA. Differential inhibition and posttranslational modification of protein phosphatase 1 and 2A in MCF7 cells treated with calyculin-A, okadaic acid, and tautomycin. J Biol Chem. 1997; 272: 13856-63.
38. Chen CS, Weng SC, Tseng PH, et al. Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J Biol Chem. 2005; 280: 38879-87.
39. Butler LM, Agus DB, Scher HI, et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 2000; 60: 5165-70.
40. Xu W, Ngo L, Perez G, et al. Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci USA. 2006; 103: 15540-5.
41. Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007; 128: 683-92.
42. Johannessen CM, Johnson LA, Piccioni F, et al. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature. 2013; 504: 138-42.